Clinical prognostic factors within the high volume subgroup of metastatic hormone sensitive prostate cancer (mHSPC) in ENZAMET (ANZUP 1304)

Hamid, A.A.Thomas, H.Martin, A.Soon, Y.Y.Horvath, L.G.Zielinski, R.Thomson, A.Tan, H.Sandhu, S.K.Reaume, M.N.Pook, D.W.Parnis, F.McDermott, R.S.Lawrence, N.Frydenberg, M.Chi, K.N.Stockler, M.R.Davis, I.D.Sweeney, C.2025-10-282025-10-282024Abstracts of the European Society for Medical Oncology Congress (ESMO 2024), as published in Annals of Oncology, 2024, vol.35, iss.Suppl. 2, pp.S977-S9780923-75341569-8041https://hdl.handle.net/2440/148019Abstract #1618Pen© 2024 Published by Elsevier Ltd.Clinical prognostic factors within the high volume subgroup of metastatic hormone sensitive prostate cancer (mHSPC) in ENZAMET (ANZUP 1304)Conference item10.1016/j.annonc.2024.08.1699735063